Interestingly, Nepstad, et al. characterized metabolic differences between primary AML cells sensitive and resistant to PI3K/Akt/mTOR inhibitors, including rapamycin, tracing them among glutamine and lipid metabolism [42]. The gene discussed is MTOR; the disease is acute myeloid leukemia.